It’s nearly been two months since we started this accidental weekly column about layoffs happening within startups. Workforce reductions have impacted startup employees in every massive sector, from crypto to SaaS to edtech and mobility. And what felt at first like a trend that only impacted growth-stage startups that had gotten over their skis, a much wider swath of companies has begun letting employees know they are making meaningful cuts.

TechCrunch listed this week’s known and confirmed layoffs below:

Ro cuts 18% of staff despite narrowing focus, raising additional capital

Ro, a healthcare unicorn that last raised $150 million just months ago at a $7 billion valuation, has cut 18% of its staff to “manage expenses, increase the efficiency of our organization and better map our resources to our current strategy,” leadership wrote in an email obtained by TechCrunch and confirmed by multiple sources.

“Due to our obligation to protect patient healthcare information, there will not be a transition period for those departing the company,” the email continues. “We know that this will feel abrupt and hope you can find alternative ways to connect to say goodbye to your teammates.” Impacted employees will get two months of severance pay and support for job placement. The healthcare unicorn is offering two months of paid healthcare benefits.

Ro confirmed the news to TechCrunch and provided a copy of the aforementioned email that CEO Zachariah Reitano sent to staff. A spokeswoman said that Ro is still hiring.

Ro’s decision to lay people off comes after a number of executives left the company, including Ro COO George Koveos, GM of Ro Pharmacy Steve Buck and most recently, Modern Fertility co-founder Afton Vechery. Vechery’s departure, which happened around one year after her company was acquired by Ro, has been rumored for over six months — first sparked by an employee exodus that peaked last year. At that time, former and current employees spoke about rising tensions at Ro that were caused by the health tech company’s inability to gain meaningful revenue from newer products.